Dyadic International Inc. (NASDAQ:DYAI – Get Free Report) saw a large drop in short interest in October. As of October 30th, there was short interest totaling 83,236 shares, a drop of 57.3% from the October 15th total of 194,728 shares. Currently, 0.3% of the shares of the stock are short sold. Based on an average daily volume of 83,778 shares, the short-interest ratio is currently 1.0 days.
Institutional Investors Weigh In On Dyadic International
An institutional investor recently bought a new position in Dyadic International stock. BlackRock Inc. purchased a new position in shares of Dyadic International Inc. (NASDAQ:DYAI – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 197,749 shares of the biotechnology company’s stock, valued at approximately $177,000. BlackRock Inc. owned 0.54% of Dyadic International at the end of the most recent quarter. 27.95% of the stock is currently owned by institutional investors and hedge funds.
Dyadic International Price Performance
Shares of NASDAQ:DYAI traded up $0.00 during midday trading on Tuesday, hitting $0.32. The company had a trading volume of 6,429 shares, compared to its average volume of 170,367. Dyadic International has a twelve month low of $0.30 and a twelve month high of $1.60. The stock has a market cap of $12.98 million, a price-to-earnings ratio of -1.54 and a beta of 1.10. The business’s 50-day simple moving average is $0.41 and its 200-day simple moving average is $0.73.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings lowered shares of Dyadic International from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 16th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company has a consensus rating of “Sell”.
View Our Latest Research Report on DYAI
Dyadic International Company Profile
Dyadic International is a biotechnology company developing microbial expression systems to produce proteins for human and animal health applications. Its platforms are designed to help partners develop and manufacture biologics, including vaccines, therapeutics and diagnostic products. The company’s technologies include its C1 fungal expression system, based on a non-pathogenic microorganism, and its Dapibus yeast platform. Dyadic licenses these systems and related expertise to collaborators and also pursues development of selected products for health applications.
See Also
- Five stocks we like better than Dyadic International
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.
